Gross-To-Net Considerations for Launching Specialty and Specialty-Lite Products


The growth of specialty and specialty-lite drugs means that manufacturers have to contend with channel design and pricing challenges as they approach commercialization and beyond. In addition, manufacturers launching their first specialty-lite drug must understand how this affects their gross-to-net (GTN) when compared to traditional specialty launches.

Jennifer Sharpe, Vice President of Gross-to-Net Consulting and Reena Patel, Partner at Blue Fin Group discussed the following:

  • The difference between specialty and specialty-lite drug therapies
  • The nuance of specialty-lite drugs as it relates to GTN when compared to specialty drugs
  • Considerations for channel strategies and WAC price
  • Forecasting methodologies for specialty-lite drugs

Jennifer Sharpe
Vice President, Gross-To-Net Consulting

Reena Patel
Partner, Blue Fin Group

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article